Janux Therapeutics Inc
JANX
Company Profile
Business description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Contact
10955 Vista Sorrento Parkway
Suite 200
San DiegoCA92130
USAT: +1 858 751-4493
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
91
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.70 | 70.60 | -0.80% |
| CAC 40 | 7,766.21 | 41.96 | -0.54% |
| DAX 40 | 24,060.29 | 100.35 | -0.42% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,938.32 | 59.74 | -0.66% |
| HKSE | 24,590.12 | 386.80 | 1.60% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,692.78 | 14.76 | 0.04% |
| NZX 50 Index | 12,747.23 | 57.60 | 0.45% |
| S&P 500 | 6,243.76 | 24.80 | -0.40% |
| S&P/ASX 200 | 8,557.00 | 73.30 | -0.85% |
| SSE Composite Index | 3,505.00 | 14.65 | -0.42% |